Incyte and Genesis Molecular AI have announced an expansion of their strategic collaboration aimed at accelerating the discovery and development of novel medicines through artificial intelligence-powered drug design technologies. The collaboration strengthens efforts to combine advanced AI capabilities with proprietary scientific data to improve the speed and efficiency of drug development programs.

The expanded agreement builds on the companies’ initial partnership announced in February 2025 and marks one of the first large-scale collaborations between a pharmaceutical company and an AI drug discovery platform involving foundation model training using proprietary experimental data.

Under the expanded collaboration, Incyte will securely provide proprietary experimental data to support training and optimisation of Genesis Molecular AI’s next-generation GEMS platform — Genesis Exploration of Molecular Space — which integrates predictive and generative artificial intelligence models designed for molecular structure prediction, protein-ligand analysis and drug molecule optimisation.

The enhanced partnership broadens the application of Genesis’ AI technologies across a larger number of complex therapeutic targets within Incyte’s research portfolio. The collaboration is intended to accelerate the identification and advancement of differentiated small-molecule medicines across multiple disease areas.

Pablo J. Cagnoni, President of Incyte and Global Head of Research and Development, said, “The expansion reflects strong outcomes from the initial collaboration and aligns with the company’s strategy of leveraging advanced technologies to strengthen drug discovery efforts. Combining Incyte’s experimental research capabilities and scientific expertise with Genesis’ AI platform could improve efficiency in advancing high-priority drug programs and help deliver innovative therapies to patients faster.

Evan Feinberg, Founder and Chief Executive Officer of Genesis Molecular AI, said proprietary experimental datasets represent a critical resource in advancing molecular artificial intelligence capabilities. He added that the collaboration establishes an industrial-scale framework integrating AI-enabled design, testing and optimization cycles to accelerate pharmaceutical innovation.

As part of the agreement, Genesis will receive total upfront consideration of USD 120 million, including an USD 80 million upfront payment and a USD 40 million equity investment by Incyte. In addition, Incyte will provide recurring research funding to support AI model training and computing infrastructure requirements.

The expanded collaboration will initially include at least five new research targets selected by Incyte, with opportunities to nominate additional targets over time. Incyte will retain exclusive rights to develop and commercialize products arising from the collaboration.

Genesis may also receive milestone payments tied to preclinical development, clinical progress, regulatory achievements and commercial sales performance. Potential milestone payments could exceed USD 1 billion across the initial five programs if development and commercial targets are achieved. Additional financial incentives are linked to future collaboration targets and product performance milestones.

Genesis Molecular AI’s GEMS platform combines artificial intelligence and physics-based modeling technologies to generate and optimize drug molecules. Its portfolio includes Pearl, a generative diffusion model developed for molecular structure prediction and drug design applications.

Headquartered in the San Francisco Bay Area, Genesis Molecular AI operates additional facilities in San Diego and New York and is supported by investors across artificial intelligence and life sciences sectors.

The expanded partnership reflects a growing trend across the pharmaceutical industry toward integrating artificial intelligence into drug discovery workflows to improve development timelines, increase efficiency and advance next-generation therapeutics.